Immunoglobulin A nephropathy (IgAN) is a serious, progressive, immune complex–mediated kidney disease. Being a rare disease, a key challenge for the evaluation of potential new treatments for IgAN is that the progression to end-stage kidney disease typically evolves over many years. Therefore, there is interest in defining earlier surrogate endpoints to serve as reliable predictors of treatment effect on long-term IgAN kidney outcomes.
No takes yet. Share an insight, caveat, or question.
Lafayette et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: